0RFI Stock Overview
BRAIN Biotech AG engages in the research and development of Bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
BRAIN Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.80 |
| 52 Week High | €5.26 |
| 52 Week Low | €2.78 |
| Beta | 1.28 |
| 1 Month Change | -18.60% |
| 3 Month Change | n/a |
| 1 Year Change | -52.54% |
| 3 Year Change | n/a |
| 5 Year Change | -74.74% |
| Change since IPO | -70.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RFI | GB Chemicals | GB Market | |
|---|---|---|---|
| 7D | -1.1% | 2.8% | 1.0% |
| 1Y | -52.5% | -35.0% | 3.0% |
Return vs Industry: 0RFI underperformed the UK Chemicals industry which returned -35% over the past year.
Return vs Market: 0RFI underperformed the UK Market which returned 3% over the past year.
Price Volatility
| 0RFI volatility | |
|---|---|
| 0RFI Average Weekly Movement | n/a |
| Chemicals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0RFI's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0RFI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 311 | Aryan Moelker | www.brain-biotech.com |
BRAIN Biotech AG engages in the research and development of Bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. It operates in three segments: BioProducts, BioScience, and BioIncubator. The company offers enzymes and biocatalysts to produce food and beverages, wound care preparations or lubricants, and production of starch and bioethanol; and microorganisms as the functional biomass for optimized industrial production processes, recycling of the greenhouse gas CO2 as an industrial raw material, and urban and green mining for extraction of precious and rare earth metals.
BRAIN Biotech AG Fundamentals Summary
| 0RFI fundamental statistics | |
|---|---|
| Market cap | €60.74m |
| Earnings (TTM) | -€8.39m |
| Revenue (TTM) | €55.23m |
1.1x
P/S Ratio-7.2x
P/E RatioIs 0RFI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RFI income statement (TTM) | |
|---|---|
| Revenue | €55.23m |
| Cost of Revenue | €24.82m |
| Gross Profit | €30.40m |
| Other Expenses | €38.80m |
| Earnings | -€8.39m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 28, 2024
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 55.05% |
| Net Profit Margin | -15.20% |
| Debt/Equity Ratio | 0% |
How did 0RFI perform over the long term?
See historical performance and comparison